EP Patent

EP4289416A2 — Drug eluting ocular implant

Assigned to Glaukos Corp · Expires 2023-12-13 · 2y expired

What this patent protects

A drug delivery ocular implant, comprising an outer shell (54) comprising an interior lumen (58) configured to contain a drug (62). The implant comprises a region of drug release (56) at a first end of the outer shell (54). The region of drug release comprises an orifice (56a, 56…

USPTO Abstract

A drug delivery ocular implant, comprising an outer shell (54) comprising an interior lumen (58) configured to contain a drug (62). The implant comprises a region of drug release (56) at a first end of the outer shell (54). The region of drug release comprises an orifice (56a, 56b). The implant also comprises a retention means (359) and a permeable or semi-permeable material disposed within the outer shell (54) and positioned between the interior lumen (58) configured to contain the drug (62) and the orifice (56a, 56b).

Drugs covered by this patent

Patent Metadata

Patent number
EP4289416A2
Jurisdiction
EP
Classification
—
Expires
2023-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Glaukos Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.